|
CN107252489A
(zh)
|
2009-04-13 |
2017-10-17 |
法国健康和医学研究院 |
Hpv颗粒及其用途
|
|
SG11201505858VA
(en)
|
2013-01-28 |
2015-09-29 |
St Jude Childrens Res Hospital |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
WO2015042325A1
(en)
|
2013-09-18 |
2015-03-26 |
Aura Biosciences, Inc. |
Virus-like particle conjugates for diagnosis and treatment of tumors
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
EP3858379A1
(en)
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
|
US10676528B2
(en)
*
|
2013-12-06 |
2020-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
|
NZ759969A
(en)
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US11982672B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
SG10201808811QA
(en)
|
2014-04-10 |
2018-11-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Method and compositions for cellular immunotherapy
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
AU2015357535B2
(en)
|
2014-12-05 |
2020-05-14 |
Eureka Therapeutics, Inc. |
Antibodies targeting G-protein coupled receptor and methods of use
|
|
US20170296623A1
(en)
*
|
2014-12-17 |
2017-10-19 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
|
HRP20240357T1
(hr)
*
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
EP3250611B1
(en)
*
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
HRP20220890T1
(hr)
*
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
MA41962A
(fr)
|
2015-04-23 |
2018-02-28 |
Baylor College Medicine |
Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507108D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
EP3288570A4
(en)
*
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
CN107849102B
(zh)
*
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
MX2017015239A
(es)
*
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
GB201509413D0
(en)
*
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
ES2958720T3
(es)
*
|
2015-06-10 |
2024-02-13 |
Immunitybio Inc |
Células NK-92 modificadas para tratar el cáncer
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
MX2018001568A
(es)
*
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
|
GB201514874D0
(en)
*
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
EP3858388B1
(en)
|
2015-09-28 |
2024-07-03 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
KR20180095511A
(ko)
*
|
2015-10-30 |
2018-08-27 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
표적화된 암 요법
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
SG11201807489PA
(en)
*
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
US10222369B2
(en)
*
|
2016-05-17 |
2019-03-05 |
Chimera Bioengineering, Inc. |
Methods for making novel antigen binding domains
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
CN117298260A
(zh)
*
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
US20190359989A1
(en)
*
|
2016-09-09 |
2019-11-28 |
Carsgen Therapeutics Co., Ltd. |
Fusion protein and applications thereof
|
|
WO2018064602A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
CA3042613A1
(en)
*
|
2016-11-11 |
2018-05-17 |
Autolus Limited |
Chimeric antigen receptor
|
|
CN118581046A
(zh)
|
2016-11-22 |
2024-09-03 |
新加坡国立大学 |
用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
|
|
WO2018111763A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
EP3568406A4
(en)
*
|
2017-01-10 |
2020-10-21 |
The General Hospital Corporation |
T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
|
|
US20190375815A1
(en)
*
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
AU2018251788B2
(en)
|
2017-04-12 |
2025-04-10 |
Aura Biosciences, Inc. |
Targeted combination therapy
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
WO2018211244A1
(en)
*
|
2017-05-15 |
2018-11-22 |
Autolus Limited |
A cell comprising a chimeric antigen receptor (car)
|
|
CN118853581A
(zh)
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
WO2019025800A1
(en)
*
|
2017-08-02 |
2019-02-07 |
Autolus Limited |
CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
|
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
PL3688155T3
(pl)
|
2017-09-28 |
2023-09-11 |
Immpact-Bio Ltd. |
Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
|
|
US11905528B2
(en)
*
|
2017-10-12 |
2024-02-20 |
Icell Gene Therapeutics Inc. |
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
CA3078963A1
(en)
|
2017-10-25 |
2019-05-02 |
Actinium Pharmaceuticals, Inc. |
Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
CN112004829A
(zh)
*
|
2018-03-12 |
2020-11-27 |
南克维斯特公司 |
Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
US20200063100A1
(en)
|
2018-05-11 |
2020-02-27 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
WO2019220109A1
(en)
|
2018-05-15 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
JP7584299B2
(ja)
|
2018-05-23 |
2024-11-15 |
ナショナル ユニバーシティ オブ シンガポール |
Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
SG11202102781UA
(en)
|
2018-09-27 |
2021-04-29 |
Autolus Ltd |
Chimeric antigen receptor
|
|
KR20210072797A
(ko)
|
2018-10-05 |
2021-06-17 |
세인트 안나 킨더크렙스포르슝 |
키메라 항원 수용체(car) 그룹
|
|
JP2022512594A
(ja)
*
|
2018-10-05 |
2022-02-07 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体（ｃａｒ）の群
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
ES3051182T3
(en)
|
2019-01-23 |
2025-12-26 |
Miltenyi Biotec Bv & Co Kg |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
EP3934666A1
(en)
|
2019-03-08 |
2022-01-12 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
BR112021021608A2
(pt)
|
2019-04-30 |
2021-12-21 |
Atara Biotherapeutics Inc |
Células car-t direcionadas a cd19 específicas para antígeno
|
|
JP7711945B2
(ja)
|
2019-04-30 |
2025-07-23 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ受容体及びその使用方法
|
|
MX2021013218A
(es)
*
|
2019-05-01 |
2021-12-10 |
Pact Pharma Inc |
Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
|
|
EP3969482A1
(en)
*
|
2019-05-16 |
2022-03-23 |
University of Washington |
Lockr-mediated recruitment of car t cells
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
US20220257757A1
(en)
|
2019-07-16 |
2022-08-18 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
EP4017510A4
(en)
*
|
2019-08-20 |
2023-11-22 |
Senti Biosciences, Inc. |
CHIMERIC INHIBITOR RECEPTOR
|
|
US12702708B2
(en)
|
2019-08-21 |
2026-08-11 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
US20220401537A1
(en)
*
|
2019-09-16 |
2022-12-22 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
|
WO2021068068A1
(en)
*
|
2019-10-08 |
2021-04-15 |
Provincial Health Services Authority |
Chimeric cytokine receptors
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
WO2021108670A1
(en)
*
|
2019-11-26 |
2021-06-03 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
WO2021119489A1
(en)
*
|
2019-12-11 |
2021-06-17 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
CN115066249A
(zh)
|
2020-02-04 |
2022-09-16 |
美天施生物科技有限两合公司 |
表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
|
|
CN115298209A
(zh)
*
|
2020-02-20 |
2022-11-04 |
森迪生物科学公司 |
抑制性嵌合受体构造体
|
|
WO2021168317A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Senti Biosciences, Inc. |
Inhibitory chimeric receptor architectures
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
US11433100B2
(en)
|
2020-08-20 |
2022-09-06 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
WO2022040454A1
(en)
*
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
EP4058474B1
(en)
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
|
|
EP4208176A4
(en)
*
|
2020-09-04 |
2025-06-25 |
Gavish-Galilee Bio Applications Ltd. |
Constructs of the bicistronic inhibiting chimeric antigen receptor (ICAR)/activating chimeric antigen receptor (ACAR) for use in cancer therapies
|
|
US20220090015A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with multiplex and localized activity
|
|
CN116648260A
(zh)
*
|
2020-10-15 |
2023-08-25 |
小利兰·斯坦福大学董事会 |
用于抑制自然杀伤细胞受体的组合物和方法
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
IL304857A
(en)
|
2021-02-16 |
2023-10-01 |
A2 Biotherapeutics Inc |
Preparations and methods for treating HER2 POSITIVE cancer
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
JP2024520430A
(ja)
*
|
2021-05-26 |
2024-05-24 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
阻害性キメラ抗原受容体は養子細胞治療のオンターゲット・オフ腫瘍効果を防止する
|
|
US20240336903A1
(en)
*
|
2021-08-19 |
2024-10-10 |
Shandong Boan Biotechnology Co., Ltd. |
Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
JP2025516531A
(ja)
|
2022-05-11 |
2025-05-30 |
オートラス リミテッド |
高リスクまたは再発性小児急性リンパ芽球性白血病のｃｄ１９／２２ ｃａｒ ｔ細胞処置
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|
|
GB202417285D0
(en)
|
2024-11-25 |
2025-01-08 |
Univ Oxford Innovation Ltd |
Expanded t cell population
|
|
WO2026120164A1
(en)
*
|
2024-12-05 |
2026-06-11 |
Essand, Magnus |
Cell-based therapy
|
|
GB202418460D0
(en)
|
2024-12-16 |
2025-01-29 |
Univ Oxford Innovation Ltd |
Multivalent binding proteins
|